⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HOTH News
Hoth Therapeutics, Inc. Common Stock
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
prnewswire.com
HOTH
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities
prnewswire.com
HOTH
Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities
prnewswire.com
HOTH